Penson named chair of Science & Quality Council at American Urological Association

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

David Penson was named chair of the Science & Quality Council at the American Urological Association. He will assume the role of chair-elect on June 1 and begin his two-year term as chair on June 2018.

As council chair, Penson is expected to provide strategic oversight to shape and execute the broad science, quality, and data agenda of the AUA. This includes supporting and expanding the AUA Quality Registry, and developing and disseminating evidence-based guidelines, patient safety and quality improvement initiatives, physician performance measures and white papers.

He will also oversee the activities of the following AUA committees: Data, Practice Guidelines and Quality Improvement & Patient Safety.

Penson is the former chair of the AUA Public Policy Council and previously held leadership positions on the AUA Quality Improvement and Patient Safety Committee and AUA Practice Guidelines Committee. He was also the AUA representative to the American College of Surgeons Commission on Cancer and the National Quality Forum.

Table of Contents

YOU MAY BE INTERESTED IN

If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.
Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login